Oragenics, Inc. Announces Expiration Of Its Investment Banking Engagement Agreement
Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that its engagement agreement with its investment